
产品介绍 评论(0)
物种
Human分子别名
CLM-8, CMRF-35-H9, CMRF35-H9, CMRF35-H, IRC1, IRC2, IgSF12, IRp60, CMRF35H, IGSF12Accession
Q9UGN4-1表达序列
Leu18-Gln178, with C-terminal hIgG1 Fc
表达宿主
HEK293分子量
45-55kDa (Reducing)
纯度
>95% by SDS-PAGE内毒素含量
<0.1EU/μg标记
Unconjugated性状
Lyophilized Powder缓冲体系
PBS, pH7.4.
溶解方法
Reconstitute at 0.1-1 mg/ml according to the size in ultrapure water after rapid centrifugation.
储存条件
· 12 months from date of receipt, lyophilized powder stored at -20 to -80℃.
· 3 months, -20 to -80℃ under sterile conditions after reconstitution.
· 1 week, 2 to 8℃ under sterile conditions after reconstitution.
· Please avoid repeated freeze-thaw cycles.
文献引用
1. Ze Tang, Hongfei Cai, Rui Wang, and Youbin Cui. Overexpression of CD300A inhibits progression of NSCLC through downregulating Wnt/β-catenin pathway. Onco Targets Ther. 2018 Dec 7:11:8875-8883. eCollection 2018.
CD300A, also known as IRp60, is a type I transmembrane glycoprotein receptor of the CD300 glycoprotein family. It is located on the surface of cell membranes.CD300A is differentially expressed on the surface of various blood cells, including T lymphocytes, B lymphocytes, natural killer (NK) cells, neutrophils, and monocytes, and is involved in the regulation of cell growth, proliferation, apoptosis, differentiation, and immune regulation. Increasing evidences show that CD300A also plays a role in the development of hematological malignancies. Jiang et al revealed that knockdown of CD300A by shRNA interference could inhibit cell growth and division in diffuse large B-cell lymphoma (DLBCL) cells, but has no effect on cell apoptosis.In acute myeloid leukemia (AML), knockdown of CD300A also decreases cell proliferation and migration and induces cell apoptosis. However, whether CD300A plays a role in the progression of solid tumors remains unclear.
电泳
1μg (R: reducing condition, N: non-reducing condition).







评论(0)